Discovered via FR Phase F cross-poll signals 2026-05-20; pending audit.
No exits recorded yet.
0 funds tracked, 0 portfolio companies (0 active · 0 realized). Verified weekly from public filings and deal announcements.
CapVest Partners is a European mid-market private equity firm headquartered in London, United Kingdom, with additional offices in New York and Dublin. Founded in 1999, it operates as a private equity manager and describes itself as a principal investor rather than an agent. The firm runs a series of flagship buyout funds, with CapVest Equity Partners V at approximately €3.8 billion and CapVest Fund VI closing in April 2026 at €4.5 billion, plus a continuation fund raised in 2025. Assets under management sat in the €4 to €4.5 billion range as of December 2024, ahead of the Fund VI close which materially increases that base. The firm has completed more than 50 investments across Europe and North America since inception.
CapVest targets resilient cash-generative businesses in non-discretionary sectors, primarily consumer staples, healthcare and essential services, where end-demand is structurally defensive. It acquires controlling stakes and partners with strong management teams to drive transformation through a combination of organic growth and acquisition-led buy-and-build consolidation, deliberately running a small focused portfolio. Geography centres on Western Europe and North America. Tickets are mid-to-large buyout scale, consistent with multi-billion-euro flagship funds. The limited partner base comprises institutional investors backing its closed-end funds. The core value-creation lever is sector consolidation: identifying companies with a clear pathway to transformation and using both organic initiatives and bolt-on M&A to build category leaders, supported by responsible-investment practices.
Recent investments include STADA Arzneimittel in healthcare and pharmaceuticals (2025) and Raymundo in food and beverage (2024), alongside portfolio holdings Curium in healthcare, NextPharma in healthcare and Inspired Pet Nutrition in consumer products. Recent exits include Curium Pharma in healthcare (2026), Valeo Foods in food and beverage (2021) and Eight Fifty Food Group in food and beverage (2021). The platform continues to deploy across resilient non-discretionary sectors in Western Europe and North America. Detailed buyer names and multiple data available on Pro at €49/month.
Other private equity firms tracked on GP Intel.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in